Siplizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Siplizumab
DrugBank Accession Number
DB06371
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Db06371
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Siplizumab
External IDs
  • MEDI-507

Pharmacology

Indication

Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.

TargetActionsOrganism
UT-cell surface antigen CD2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Siplizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Siplizumab.
AducanumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Siplizumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Siplizumab is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
KUW1QG1ZM3
CAS number
288392-69-8

References

General References
Not Available
Wikipedia
Siplizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentKidney Transplantation / Renal Failure, Chronic Renal Failure1
2CompletedTreatmentPsoriasis (PsO)1
2CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes (MDS)1
1Active Not RecruitingTreatmentGamma Delta Hepatosplenic T-Cell Lymphoma / Peripheral T Cell Lymphoma (PTCL) / Subcutaneous Panniculitis Like T Cell Lymphoma / T-NK Cell Lymphoma1
1CompletedTreatmentGraft Versus Host Disease (cGvHD)2
1CompletedTreatmentGraft Versus Host Disease (cGvHD) / Malignancies1
1CompletedTreatmentKidney Diseases1
1Not Yet RecruitingTreatmentKidney Failure1
1TerminatedTreatmentDisorders, Lymphoproliferative1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytopla...
Gene Name
CD2
Uniprot ID
P06729
Uniprot Name
T-cell surface antigen CD2
Molecular Weight
39447.96 Da

Drug created on March 19, 2008 16:27 / Updated on February 21, 2021 18:52